Joel Beatty
Stock Analyst at Baird
(4.23)
# 489
Out of 4,479 analysts
106
Total ratings
36.07%
Success rate
25.47%
Average return
Main Sectors:
49 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Maintains: Outperform | $7 → $6 | $1.88 | +219.15% | 4 | Jun 27, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $15 | $10.82 | +38.63% | 2 | Jun 11, 2024 | |
| NGNE Neurogene | Initiates: Outperform | $54 | $38.46 | +40.41% | 1 | Jun 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $68 → $72 | $40.96 | +75.78% | 4 | May 31, 2024 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $27 | $6.96 | +287.93% | 1 | May 28, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Neutral | $104 → $72 | $82.22 | -12.43% | 4 | May 17, 2024 | |
| CLDI Calidi Biotherapeutics | Maintains: Outperform | $4.5 → $2 | $0.20 | +888.14% | 3 | May 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $31 → $28 | $15.84 | +76.77% | 3 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $108 → $112 | $78.93 | +41.90% | 2 | May 7, 2024 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $117 | $39.27 | +197.94% | 1 | May 1, 2024 | |
| LBPH Longboard Pharmaceuticals | Initiates: Outperform | $36 | $30.74 | +17.11% | 1 | May 1, 2024 | |
| GERN Geron | Downgrades: Neutral | $4.5 | $4.17 | +7.91% | 2 | Apr 30, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Outperform | $83 → $103 | $68.54 | +50.28% | 2 | Apr 17, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $24 → $25 | $18.93 | +32.07% | 2 | Apr 11, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $4 → $3 | $1.74 | +72.41% | 3 | Apr 11, 2024 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $11 → $9 | $1.69 | +432.54% | 2 | Mar 19, 2024 | |
| ALKS Alkermes | Initiates: Outperform | $37 | $24.19 | +52.96% | 1 | Mar 19, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $505 → $490 | $435.49 | +12.52% | 3 | Mar 1, 2024 | |
| COGT Cogent Biosciences | Downgrades: Neutral | $14 → $8 | $8.24 | -2.91% | 2 | Feb 26, 2024 | |
| ELF e.l.f. Beauty | Initiates: Neutral | $185 | $204.23 | -9.42% | 1 | Jan 30, 2024 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Outperform | $160 | $105.09 | +52.25% | 1 | Jan 3, 2024 | |
| VAXX Vaxxinity | Initiates: Outperform | $7 | $0.27 | +2,446.38% | 1 | Sep 8, 2023 | |
| TCON TRACON Pharmaceuticals | Maintains: Outperform | $140 → $60 | $0.95 | +6,215.79% | 3 | Aug 15, 2023 | |
| INMB INmune Bio | Initiates: Outperform | $16 | $8.07 | +98.27% | 1 | Jun 1, 2023 | |
| CMRX Chimerix | Initiates: Outperform | $7 | $0.86 | +711.59% | 1 | May 23, 2023 | |
| BYSI BeyondSpring | Maintains: Outperform | $4 → $1.25 | $2.36 | -47.03% | 2 | May 2, 2023 | |
| PLRX Pliant Therapeutics | Initiates: Outperform | $44 | $10.60 | +315.09% | 3 | Apr 13, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $60 → $58 | $25.22 | +129.98% | 2 | Feb 7, 2023 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $18 → $24 | $33.72 | -28.83% | 2 | Nov 18, 2022 | |
| EDIT Editas Medicine | Maintains: Outperform | $25 → $18 | $4.54 | +296.48% | 2 | Nov 18, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Underperform | $18 | $21.48 | -16.20% | 3 | Nov 10, 2022 | |
| CRDF Cardiff Oncology | Maintains: Outperform | $9 → $6 | $2.08 | +188.46% | 2 | Aug 29, 2022 | |
| IGMS IGM Biosciences | Maintains: Outperform | $46 → $31 | $6.40 | +384.38% | 2 | Jun 1, 2022 | |
| VIR Vir Biotechnology | Upgrades: Neutral | $36 → $28 | $8.85 | +216.38% | 2 | Mar 3, 2022 | |
| BPMC Blueprint Medicines | Maintains: Outperform | n/a | $110.36 | - | 1 | Jun 17, 2021 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | n/a | $247.61 | - | 2 | Feb 12, 2021 | |
| VNDA Vanda Pharmaceuticals | Downgrades: Neutral | n/a | $5.27 | - | 4 | Jan 14, 2021 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | n/a | $154.20 | - | 2 | Jan 12, 2021 | |
| PTCT PTC Therapeutics | Upgrades: Buy | n/a | $30.39 | - | 5 | Jan 5, 2021 | |
| ELOX Eloxx Pharmaceuticals | Downgrades: Neutral | n/a | $0.73 | - | 1 | Jun 11, 2020 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | n/a | $45.14 | - | 2 | Apr 9, 2020 | |
| DBVT DBV Technologies | Maintains: Buy | $28 → $20 | $0.77 | +2,491.01% | 2 | Apr 6, 2020 | |
| AMRN Amarin Corporation | Maintains: Buy | n/a | $0.71 | - | 3 | Apr 1, 2020 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | n/a | $0.54 | - | 1 | Mar 26, 2020 | |
| ESPR Esperion Therapeutics | Upgrades: Buy | n/a | $2.34 | - | 5 | Mar 17, 2020 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | n/a | $20.66 | - | 1 | Oct 11, 2018 | |
| ASNS Actelis Networks | Maintains: Neutral | n/a | $1.74 | - | 2 | Aug 17, 2018 | |
| NVAX Novavax | Maintains: Neutral | n/a | $12.97 | - | 3 | Feb 21, 2018 | |
| KURA Kura Oncology | Maintains: Buy | n/a | $20.58 | - | 1 | Nov 10, 2017 |
Immutep
Jun 27, 2024
Maintains: Outperform
Price Target: $7 → $6
Current: $1.88
Upside: +219.15%
Sage Therapeutics
Jun 11, 2024
Maintains: Neutral
Price Target: $15
Current: $10.82
Upside: +38.63%
Neurogene
Jun 11, 2024
Initiates: Outperform
Price Target: $54
Current: $38.46
Upside: +40.41%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $40.96
Upside: +75.78%
Mind Medicine (MindMed)
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $6.96
Upside: +287.93%
BioMarin Pharmaceutical
May 17, 2024
Downgrades: Neutral
Price Target: $104 → $72
Current: $82.22
Upside: -12.43%
Calidi Biotherapeutics
May 15, 2024
Maintains: Outperform
Price Target: $4.5 → $2
Current: $0.20
Upside: +888.14%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $15.84
Upside: +76.77%
Axsome Therapeutics
May 7, 2024
Maintains: Outperform
Price Target: $108 → $112
Current: $78.93
Upside: +41.90%
Praxis Precision Medicines
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $39.27
Upside: +197.94%
Longboard Pharmaceuticals
May 1, 2024
Initiates: Outperform
Price Target: $36
Current: $30.74
Upside: +17.11%
Geron
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $4.17
Upside: +7.91%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $68.54
Upside: +50.28%
Nurix Therapeutics
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $18.93
Upside: +32.07%
Amylyx Pharmaceuticals
Apr 11, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.74
Upside: +72.41%
Leap Therapeutics
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $1.69
Upside: +432.54%
Alkermes
Mar 19, 2024
Initiates: Outperform
Price Target: $37
Current: $24.19
Upside: +52.96%
argenx SE
Mar 1, 2024
Maintains: Outperform
Price Target: $505 → $490
Current: $435.49
Upside: +12.52%
Cogent Biosciences
Feb 26, 2024
Downgrades: Neutral
Price Target: $14 → $8
Current: $8.24
Upside: -2.91%
e.l.f. Beauty
Jan 30, 2024
Initiates: Neutral
Price Target: $185
Current: $204.23
Upside: -9.42%
Jazz Pharmaceuticals
Jan 3, 2024
Initiates: Outperform
Price Target: $160
Current: $105.09
Upside: +52.25%
Vaxxinity
Sep 8, 2023
Initiates: Outperform
Price Target: $7
Current: $0.27
Upside: +2,446.38%
TRACON Pharmaceuticals
Aug 15, 2023
Maintains: Outperform
Price Target: $140 → $60
Current: $0.95
Upside: +6,215.79%
INmune Bio
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $8.07
Upside: +98.27%
Chimerix
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $0.86
Upside: +711.59%
BeyondSpring
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.36
Upside: -47.03%
Pliant Therapeutics
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $10.60
Upside: +315.09%
Arrowhead Pharmaceuticals
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $25.22
Upside: +129.98%
IDEAYA Biosciences
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $33.72
Upside: -28.83%
Editas Medicine
Nov 18, 2022
Maintains: Outperform
Price Target: $25 → $18
Current: $4.54
Upside: +296.48%
Arcturus Therapeutics Holdings
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $21.48
Upside: -16.20%
Cardiff Oncology
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.08
Upside: +188.46%
IGM Biosciences
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $6.40
Upside: +384.38%
Vir Biotechnology
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $8.85
Upside: +216.38%
Blueprint Medicines
Jun 17, 2021
Maintains: Outperform
Price Target: n/a
Current: $110.36
Upside: -
Alnylam Pharmaceuticals
Feb 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $247.61
Upside: -
Vanda Pharmaceuticals
Jan 14, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.27
Upside: -
Sarepta Therapeutics
Jan 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $154.20
Upside: -
PTC Therapeutics
Jan 5, 2021
Upgrades: Buy
Price Target: n/a
Current: $30.39
Upside: -
Eloxx Pharmaceuticals
Jun 11, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.73
Upside: -
Ionis Pharmaceuticals
Apr 9, 2020
Maintains: Buy
Price Target: n/a
Current: $45.14
Upside: -
DBV Technologies
Apr 6, 2020
Maintains: Buy
Price Target: $28 → $20
Current: $0.77
Upside: +2,491.01%
Amarin Corporation
Apr 1, 2020
Maintains: Buy
Price Target: n/a
Current: $0.71
Upside: -
X4 Pharmaceuticals
Mar 26, 2020
Maintains: Buy
Price Target: n/a
Current: $0.54
Upside: -
Esperion Therapeutics
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.34
Upside: -
Syndax Pharmaceuticals
Oct 11, 2018
Maintains: Buy
Price Target: n/a
Current: $20.66
Upside: -
Actelis Networks
Aug 17, 2018
Maintains: Neutral
Price Target: n/a
Current: $1.74
Upside: -
Novavax
Feb 21, 2018
Maintains: Neutral
Price Target: n/a
Current: $12.97
Upside: -
Kura Oncology
Nov 10, 2017
Maintains: Buy
Price Target: n/a
Current: $20.58
Upside: -